Single domain antibodies as inhibitors of PCSK9
US9879093B2 · kind B2 · utility
3Cited by
1References
22Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Dec 20, 2012 |
| Grant date | Jan 30, 2018 |
| Priority date | — |
| Expiry date | Mar 6, 2035 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2333/96433
- WIPO fieldMeasurement
- WIPO sectorInstruments
Abstract
Antibodies (e.g., sdAbs) binding to PCSK9 are described. Nucleic acids encoding such Abs, host cells expressing such Abs and pharmaceutical composition comprising same are described. The use of these PCSK9-binding Abs for lowering low-density lipoprotein-cholesterol (LDL-C) levels and for the treatment of cardiovascular disorders, is also described.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.